Format

Send to

Choose Destination
Gastrointest Endosc. 2015 Sep;82(3):460-8.e2. doi: 10.1016/j.gie.2015.01.026. Epub 2015 Apr 4.

Survival and clinical outcome after endoscopic duodenal stent placement for malignant gastric outlet obstruction: comparison of pancreatic cancer and nonpancreatic cancer.

Author information

1
Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington, USA.

Abstract

BACKGROUND:

Data on endoscopic stenting of malignant gastric outlet obstruction (GOO) are based on studies predominantly involving patients with pancreatic adenocarcinoma.

OBJECTIVE:

To compare survival and clinical outcome after stent placement for GOO due to pancreatic cancer compared with nonpancreatic cancer.

DESIGN:

Retrospective study.

SETTING:

Single tertiary hospital.

PATIENTS:

A total of 292 patients with malignant GOO.

INTERVENTION:

Stent placement.

MAIN OUTCOME MEASUREMENTS:

Post-stent placement survival and clinical outcome.

RESULTS:

In 196 patients with pancreatic cancer and 96 with nonpancreatic cancer, median post-stent placement survival was similar (2.7 months in pancreatic cancer vs 2.4 months in nonpancreatic cancer). Overall survival was shorter in patients with pancreatic cancer (13.7 vs 17.1 months; P = .004). Clinical success rates at 2 months (71% vs 91%) and reintervention rates (30% vs 23%) were comparable. Post-stent placement chemotherapy and the absence of distant metastasis were associated with better post-stent placement survival in both groups (pancreatic cancer: chemotherapy vs no chemotherapy, 5.4 vs 1.5 months, P < .0001; metastasis vs no metastasis, 1.8 vs 4.6, P = .005; nonpancreatic cancer: chemotherapy vs no chemotherapy, 9.2 vs 1.8, P = .001; metastasis vs no metastasis, 2.1 vs 6.1, P = .009).

LIMITATIONS:

Retrospective study.

CONCLUSIONS:

In this large series of patients undergoing stent placement for malignant GOO in North America, we observed no difference in post-stent placement survival despite better overall survival in patients with nonpancreatic cancer. GOO is a marker for poor survival in malignancy, regardless of the type. Chemotherapy and the absence of distant metastasis were associated with better post-stent placement survival in both groups.

PMID:
25851162
DOI:
10.1016/j.gie.2015.01.026
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center